Editas Medicine Files Q1 2025 10-Q

Ticker: EDIT · Form: 10-Q · Filed: May 12, 2025 · CIK: 1650664

Sentiment: neutral

Topics: 10-Q, biotech, financials

TL;DR

Editas Medicine filed its Q1 2025 10-Q. Check financials.

AI Summary

Editas Medicine, Inc. filed its quarterly report for the period ending March 31, 2025. The company, based in Cambridge, MA, is involved in biological products. Key financial details and operational updates for the first quarter of 2025 are presented in this filing.

Why It Matters

This filing provides investors and stakeholders with the latest financial performance and operational status of Editas Medicine, Inc. as of March 31, 2025.

Risk Assessment

Risk Level: medium — Biotech companies like Editas Medicine are inherently risky due to the long development cycles, high R&D costs, and regulatory hurdles involved in bringing new therapies to market.

Key Numbers

Key Players & Entities

FAQ

What is the total cash and cash equivalents as of March 31, 2025?

The provided text does not contain specific dollar amounts for cash and cash equivalents. It only lists the reporting period end date.

What were the total revenues for the quarter ended March 31, 2025?

The provided text does not contain specific revenue figures for the quarter ended March 31, 2025.

What is the company's primary business focus?

Editas Medicine, Inc. is involved in Biological Products (NO DIAGNOSTIC SUBSTANCES) as indicated by its Standard Industrial Classification code [2836].

When was the company incorporated?

The state of incorporation for Editas Medicine, Inc. is Delaware (DE).

What is the fiscal year end for Editas Medicine, Inc.?

The fiscal year end for Editas Medicine, Inc. is December 31 (1231).

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Editas Medicine, Inc. (EDIT).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing